282 related articles for article (PubMed ID: 27370960)
21. Mannose-mediated inhibitory effects of PA-MSHA on invasion and metastasis of hepatocellular carcinoma via EGFR/Akt/IκBβ/NF-κB pathway.
Li T; Dong ZR; Guo ZY; Wang CH; Zhi XT; Zhou JW; Li DK; Chen ZT; Chen ZQ; Hu SY
Liver Int; 2015 Apr; 35(4):1416-29. PubMed ID: 25066210
[TBL] [Abstract][Full Text] [Related]
22. The NF-kappa B inhibitor, celastrol, could enhance the anti-cancer effect of gambogic acid on oral squamous cell carcinoma.
He D; Xu Q; Yan M; Zhang P; Zhou X; Zhang Z; Duan W; Zhong L; Ye D; Chen W
BMC Cancer; 2009 Sep; 9():343. PubMed ID: 19778460
[TBL] [Abstract][Full Text] [Related]
23. Gambogic acid down-regulates MDM2 oncogene and induces p21(Waf1/CIP1) expression independent of p53.
Rong JJ; Hu R; Qi Q; Gu HY; Zhao Q; Wang J; Mu R; You QD; Guo QL
Cancer Lett; 2009 Oct; 284(1):102-12. PubMed ID: 19428175
[TBL] [Abstract][Full Text] [Related]
24. Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis.
Zhao WL; Wang L; Liu YH; Yan JS; Leboeuf C; Liu YY; Wu WL; Janin A; Chen Z; Chen SJ
Exp Hematol; 2007 Dec; 35(12):1801-11. PubMed ID: 17681667
[TBL] [Abstract][Full Text] [Related]
25. AS1411-Induced Growth Inhibition of Glioma Cells by Up-Regulation of p53 and Down-Regulation of Bcl-2 and Akt1 via Nucleolin.
Cheng Y; Zhao G; Zhang S; Nigim F; Zhou G; Yu Z; Song Y; Chen Y; Li Y
PLoS One; 2016; 11(12):e0167094. PubMed ID: 27907160
[TBL] [Abstract][Full Text] [Related]
26. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance.
Vega MI; Huerta-Yepaz S; Garban H; Jazirehi A; Emmanouilides C; Bonavida B
Oncogene; 2004 Apr; 23(20):3530-40. PubMed ID: 15077178
[TBL] [Abstract][Full Text] [Related]
27. Dual targeting of retinoid X receptor and histone deacetylase with DW22 as a novel antitumor approach.
Wang L; Chen G; Chen K; Ren Y; Li H; Jiang X; Jia L; Fu S; Li Y; Liu X; Wang S; Yang J; Wu C
Oncotarget; 2015; 6(12):9740-55. PubMed ID: 25762635
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
[TBL] [Abstract][Full Text] [Related]
29. Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis.
Vega MI; Huerta-Yepez S; Jazirehi AR; Garban H; Bonavida B
Oncogene; 2005 Dec; 24(55):8114-27. PubMed ID: 16103877
[TBL] [Abstract][Full Text] [Related]
30. Ginsenoside 20(s)-Rh2 as potent natural histone deacetylase inhibitors suppressing the growth of human leukemia cells.
Liu ZH; Li J; Xia J; Jiang R; Zuo GW; Li XP; Chen Y; Xiong W; Chen DL
Chem Biol Interact; 2015 Dec; 242():227-34. PubMed ID: 26482938
[TBL] [Abstract][Full Text] [Related]
31. Suppression of NF-κB signaling and P-glycoprotein function by gambogic acid synergistically potentiates adriamycin -induced apoptosis in lung cancer.
Wang LH; Yang JY; Yang SN; Li Y; Ping GF; Hou Y; Cui W; Wang ZZ; Xiao W; Wu CF
Curr Cancer Drug Targets; 2014; 14(1):91-103. PubMed ID: 24245692
[TBL] [Abstract][Full Text] [Related]
32. Curcumin, a potent anti-tumor reagent, is a novel histone deacetylase inhibitor regulating B-NHL cell line Raji proliferation.
Liu HL; Chen Y; Cui GH; Zhou JF
Acta Pharmacol Sin; 2005 May; 26(5):603-9. PubMed ID: 15842781
[TBL] [Abstract][Full Text] [Related]
33. Histone Deacetylase Inhibitors Inhibit the Proliferation of Gallbladder Carcinoma Cells by Suppressing AKT/mTOR Signaling.
Zhang P; Guo Z; Wu Y; Hu R; Du J; He X; Jiao X; Zhu X
PLoS One; 2015; 10(8):e0136193. PubMed ID: 26287365
[TBL] [Abstract][Full Text] [Related]
34. Anti-tumoral effect of arsenic compound, sodium metaarsenite (KML001), in non-Hodgkin's lymphoma: an in vitro and in vivo study.
Yoon JS; Hwang DW; Kim ES; Kim JS; Kim S; Chung HJ; Lee SK; Yi JH; Uhm J; Won YW; Park BB; Choi JH; Lee YY
Invest New Drugs; 2016 Feb; 34(1):1-14. PubMed ID: 26581399
[TBL] [Abstract][Full Text] [Related]
35. Involvement of Chk1-Cdc25A-cyclin A/CDK2 pathway in simvastatin induced S-phase cell cycle arrest and apoptosis in multiple myeloma cells.
Tu YS; Kang XL; Zhou JG; Lv XF; Tang YB; Guan YY
Eur J Pharmacol; 2011 Nov; 670(2-3):356-64. PubMed ID: 21958871
[TBL] [Abstract][Full Text] [Related]
36. Retinoid-mediated inhibition of cell growth with stimulation of apoptosis in aggressive B-cell lymphomas.
Sundaresan A; Claypool K; Mehta K; Lopez-Berestein G; Cabanillas F; Ford RJ
Cell Growth Differ; 1997 Oct; 8(10):1071-82. PubMed ID: 9342185
[TBL] [Abstract][Full Text] [Related]
37. Eriocalyxin B induces apoptosis in lymphoma cells through multiple cellular signaling pathways.
Zhang YW; Jiang XX; Chen QS; Shi WY; Wang L; Sun HD; Shen ZX; Chen Z; Chen SJ; Zhao WL
Exp Hematol; 2010 Mar; 38(3):191-201. PubMed ID: 20045442
[TBL] [Abstract][Full Text] [Related]
38. AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas.
Qi W; Liu X; Cooke LS; Persky DO; Miller TP; Squires M; Mahadevan D
Int J Cancer; 2012 Jun; 130(12):2997-3005. PubMed ID: 21796626
[TBL] [Abstract][Full Text] [Related]
39. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
Jazirehi AR; Bonavida B
Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
[TBL] [Abstract][Full Text] [Related]
40. Wogonin as a targeted therapeutic agent for EBV (+) lymphoma cells involved in LMP1/NF-κB/miR-155/PU.1 pathway.
Wu X; Liu P; Zhang H; Li Y; Salmani JM; Wang F; Yang K; Fu R; Chen Z; Chen B
BMC Cancer; 2017 Feb; 17(1):147. PubMed ID: 28222771
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
